I had an interesting reply to my last post, Opportunity Cost, Opportunity Lost. Written by “Anonymous,” that John/Jane Doe of the internet, it went:
“Dr. Hamblin disagrees with you. He has written in January 2006 (search his blog) that the patient should have his spleen removed, have transfusions, just about be on his deathbed before starting treatment. Read his blog entry if you don't believe it.”
I follow Dr. Terry Hamblin’s blog, and I have read the entry in question, as well has his other entries on the subject, and I generally agree with his approach to treatment. In fact, one of the most important things he has done through his blog and his participation in the ACOR list has been to raise patient awareness about the limits of treatment, and to argue effectively that it should usually be the last resort, not the first.
Anonymous is assuming incorrectly that the purpose of my last post was to promote early treatment; it was merely to show that there can be opportunity costs associated with treatment decisions, including ones in which we avoid treatment at all costs (pun intended).
If we didn't have any soft-glove treatments for chronic lymphocytic leukemia -- which was the case until a few years ago -- I would probably agree with what Anonymous said Dr. Hamblin said. I would have to be at least half dead, preferably three-quarters, before starting treatment.
Of course, it is easy to say something like that, and another thing to do it. Take a splenectomy, for example. Removing a huge spleen involves major surgery, and doing it in a patient whose marrow has crashed to the point of needing transfusions makes it a much more dangerous operation than it would be in an earlier-stage patient. Is there not an opportunity cost if this hypothetical patient succumbs to operation complications or a hospital-related infection by having waited too long to deal with the spleen?
These irksome opportunity costs are lurking everywhere we CLLers turn, and they are to be ignored at our own peril. Explaining this concept was the purpose of my last post, and elaborating on it is the purpose of this one.
Float like a butterfly
Back to the point about soft-glove treatments. In 2006, we do have one -- the CD20 monoclonal antibody Rituxan (rituximab), which is likely to be followed soon by HuMax-CD20 (ofatumumab), which is now accruing patients for Phase III trials and has been accorded fast-track status by the FDA.
(Chaya Venkat of CLL Topics has written a few tantalizing lines about an even more powerful monoclonal coming down the pike, nicknamed the “B1 bomber.” And there are, of course, researchers hither and yon working on some interesting concepts such as HSP-90 inhibitors and treatments to attack the ZAP-70 protein. All of these targeted therapies -- some of which won’t pan out, and some of which will -- promise much lower toxicity than traditional chemo.)
In some patients and under some circumstances, these low-tox therapies can change the game. I view these drugs as tools -- methods, essentially, of extending watch and wait. (Or, put another way, methods of disease control, however imperfect.) While they don't come with no cost, the risk-reward scale tends to put them into a different category from traditional treatment.
To quote Dr. Hamblin, from his blog entry referenced above:
“If treatment is inevitable, my choice would be the treatment that is least harmful. At the moment this is rituximab. It only works in about half the patients, and it does lower the levels of normal B cells, but this is transient and they quickly return. Rituximab plus a growth factor like G-CSF or GM-CSF may well be more effective. So if it works for you and gives you a year off treatment then go for it, and don’t be afraid to repeat it. True rituximab resistance is very rare. In some patients increasing the dose will turn a non-responder into a responder.”
Building bridges and blowing them up
Rituxan and the coming next generation of monoclonals mean that patients may be able to build bridges into the future while still preserving hard-chemo options should they become necessary. If one can scrape by with Rituxan until HuMax arrives, then scrape by with that until the B-1 bomber takes the field, or until a monoclonal targeting something else becomes available, or until a breakthrough in vaccine or molecular or biologic therapy happens, one has made a wise use of these opportunities.
Conversely, if one hits the CLL hard at the start with what I like to call Alphabet Soup Chemo -- RF, RFC, CFAR, RFC+M, R-CHOP and the like -- one has paid a big price in terms of opportunity cost: The soft-glove drugs work best in people whose immune systems are relatively intact, and Alphabet Soup Chemo can lead to all sorts of immune problems, including neutropenia, T cell depletion, and such nasties as myelodysplastic syndrome (MDS). While CFAR is blasting away at your CLL, it is also burning your soft-glove bridges.
That said, drug response in CLL -- depth of remission, tolerance and side effects, development of disease resistance -- can be idiosyncratic and unpredictable. Rituxan is no panacea, and for some it is pretty much a wasted effort.
For others, it is a lifeline, allowing them to maintain a good quality of life for a long time. I am a Bucket C case, and my disease has progressed a bit despite my three courses of Rituxan. But I believe that Rituxan has slowed that progress. (In the irony department, is “progress” really the right concept here?) I am IgVH unmutated, now with the 11q deletion, and I have been at Stage 2 since my diagnosis three years ago. Would I have progressed by now to a later stage without the Rituxan? There is no way to know for sure, but I decided long ago that the opportunity cost of doing nothing was too great to risk finding out.
Single-agent Rituxan is not, of course, an acceptable approach to some doctors. (Among these, it seems, are a few like Lt. Col. Bill Kilgore of Apocalypse Now, who love the smell of napalm in the morning.) They would argue that there is an opportunity cost to using soft-glove treatments prematurely, that this use may render them less effective in combination therapy when and if the time comes that a patient needs a stellar, MRD-negative remission.
From what I gather, though, patients using Rituxan as a single agent do not close the door on this; the synergy between Rituxan and chemo agents seems to boost the effectiveness of both, though there may indeed be some diminution. The patient is left looking at opportunity costs and wondering: Do I let the disease go until I might need Alphabet Soup Chemo, reserving my Rituxan for the best possible remission then? Or do I try to control the disease with it now -- perhaps putting off that Alphabet Soup Chemo forever if I build my bridges right -- yet knowing that my chances of a MRD-negative remission may be somewhat reduced if I ever need one? (And, let’s add these delightful monkey wrenches: Do I assume that science will/will not come up with additional drugs that might render these costs moot in X number of years? Is a MRD-negative remission all it’s cracked up to be?)
So far -- and again, this is my personal view -- I can only see three cases where enduring the toxicities and potentially deadly complications of Alphabet Soup Chemo is worth it:
One is in a pre-transplant situation, where extreme cytoreduction is a key to success.
The second is in cases where a person’s disease is past the point of being controlled by soft-glove treatments, or by palliative means such as transfusions, and in which the benefits of Alphabet Soup Chemo decisively outweigh the risks.
The 17p dilemma (and a bit of good news)
The third, perhaps -- and this is a big “perhaps” -- is in the case of early-stage, high-risk patients. In fact, there is some debate among experts about whether early intervention may be warranted in patients with the worst cytogenetics, such as unmutated, 17p-deleted cases. In a newly-diagnosed, asymptomatic, Stage 0 patient with unmutated 17p (or even 11q) CLL, is there an opportunity cost to doing nothing? After all, the disease always progresses, fewer drugs work on 17p, and both 17p and 11q patients tend to get shorter-duration remissions. Is it better for the patient to pull out the alphabet soup and blast the disease early, go for something of a cure?
Of course, this being CLL, there is always another way of looking at things.
Here’s an interesting tidbit from a pilot study of 12 patients by Ron Taylor and company at the University of Virginia. Taylor is a leading proponent of the concept of CD20 “shaving,” and suggests that low-dose Rituxan may actually be more effective than higher-dose given the way the body’s complement system responds to the drug. The study included six patients with the 17p deletion. Patients were given either 20mg/m2 or 60mg/m2 of Rituxan three times a week for four weeks (the usual dose is 375mg/m2, so this is really low dose.) The results flew in the face of conventional wisdom, which is that Rituxan doesn’t work in 17p cases: “The two patients with the highest cell surface CD20 expression achieved CR (complete response),” the authors wrote, “despite the presence of the del 17p in both cases.”
Let me repeat that: Low-dose Rituxan has been shown to have significant activity in 17p-deleted patients with good CD 20 expression. (Of course, this needs to be studied and verified in larger groups of these patients, but this pilot study has to be welcome news to those in Bucket C-minus.)
So, assuming this good news is correct, and considering that 17p is known to quickly turn aggressive, is there an opportunity cost for such patients in not using low-dose Rituxan early on in their disease?
I cannot solve all these maddening dilemmas, just point them out. A wise person once said that the key in life is not to know all the answers, but rather to ask the right questions. For us patients, just knowing what to ask, and what considerations to balance, is trouble enough in itself. Failing to get some kind of handle on this carries its own opportunity cost: being unable to map out a workable long-term strategy, and being unprepared for the unexpected.
GET MY CAR-T CELLS TOMORROW FOR MYCLL - Patty and I have been enjoying Seattle. We’ve been here for 3 weeks prepping for the JCAR14 trial at SCCA/Hutch. Tomorrow is my big day- I get the CAR-T ce...
1 day ago